Lauren C. Harshman

Vice President

Surface Oncology Inc.

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 268 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Results from a Phase 2 Study of Triplet Blockade of the IL-27, PD-(L)1, and VEGF Pathways with Casdozokitug (casdozo, SRF388) in Combination with Atezolizumab (atezo) and Bevacizumab (bev) in Patients with Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma (Uhcc)

Daneng Li,Kun-Ming Rau,Ming-Lung Yu,Hong Jae Chon,Hsueh-Chou Lai,Meredith Pelster,Stuart K. Roberts,Oxana V. Crysler,Gina M. Vaccaro,Mark Sanders Womack,Ju Won Kim,Jin-Mo Yang,Hyung-Don Kim,Jonathan Hill,Vienna Lynn Reichert,Ricard Masia,Lauren C. Harshman,Chih-Hung Hsu,Yoon-Koo Kang

Journal of Clinical Oncologyno. 3_suppl (2024): 470-470

Cited0Views0Bibtex

Supplemental Figure 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish D. Choudhury,Lucia Kwak,Alexander Cheung,Kathryn M. Allaire,Jaqueline Marquez,David D. Yang,Abhishek Tripathi,Jacqueline M. Kilar,Meredith Flynn,Brianna Maynard,Rebecca Reichel,Amanda F. Pace,Brandon K. Chen,Eliezer M. Van Allen,Kerry Kilbridge,Xiao X. Wei,Bradley A. McGregor,Mark M. Pomerantz,Rupal S. Bhatt,Christopher J. Sweeney,Glenn J. Bubley,Heather A. Jacene,Mary-Ellen Taplin,Franklin W. Huang,Lauren C. Harshman,Lawrence Fong

crossref（2024）

Cited0Views0Bibtex

Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish D. Choudhury,Lucia Kwak,Alexander Cheung,Kathryn M. Allaire,Jaqueline Marquez,David D. Yang,Abhishek Tripathi,Jacqueline M. Kilar,Meredith Flynn,Brianna Maynard,Rebecca Reichel,Amanda F. Pace,Brandon K. Chen,Eliezer M. Van Allen,Kerry Kilbridge,Xiao X. Wei,Bradley A. McGregor,Mark M. Pomerantz,Rupal S. Bhatt,Christopher J. Sweeney,Glenn J. Bubley,Heather A. Jacene, Mary-Ellen Taplin,Franklin W. Huang,Lauren C. Harshman,Lawrence Fong

crossref（2024）

Cited0Views0Bibtex

Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Perioperative Nivolumab Versus Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER ECOG-ACRIN EA8143): an Open-Label, Randomised, Phase 3 Study

Mohamad E. Allaf,Se-Eun Kim,Viraj Master,David F. McDermott,Lauren C. Harshman,Suzanne M. Cole,Charles G. Drake,Sabina Signoretti,Mahmut Akgul,Nicholas Baniak, Elsa Li-Ning,Matthew B. Palmer,Hamid Emamekhoo,Nabil Adra,Hristos Kaimakliotis,Yasser Ged,Phillip M. Pierorazio,E. Jason Abel,Mehmet A. Bilen,Kenneth Ogan,Helen H. Moon, Krishna A. Ramaswamy,Eric A. Singer,Tina M. Mayer,Jay Lohrey,Vitaly Margulis,Jessie Gills,Scott E. Delacroix, Mark J. Waples,Andrew C. James, Peng Wang,Toni Choueiri,M. Dror Michaelson,Anil Kapoor,Daniel Y. Heng,Brian Shuch,Bradley C. Leibovich,Primo N. Lara,Judith Manola,Deborah Maskens,Dena Battle,Robert Uzzo,Gennady Bratslavsky,Naomi B. Haas,Michael A. Carducci

LANCET ONCOLOGYno. 8 (2024): 1038-1052

Cited0Views0WOSBibtex

Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Supplemental Figure 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

crossref（2024）

Cited0Views0Bibtex

Author Statistics

#Papers: 268

#Citation: 7105

H-Index: 41

G-Index: 79

Sociability: 7

Diversity: 3

Activity: 64

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn